The company is making progress with OSK Therapy (ER100) for reversing blindness and treating glaucoma.

High-stakes moonshot initiating the first human epigenetic reprogramming trial targeting glaucoma; success would validate the entire field of cellular reprogramming.

The company is entering human clinical trials for glaucoma using Yamanaka genes (OSK) to reverse cellular aging, with potential expansion into liver and brain therapies.

Received FDA clearance for partial epigenetic reprogramming in humans to treat vision loss.

A leader in epigenetic reprogramming starting human trials in January for eye diseases; success could be a major catalyst for the sector.

Positive results from its upcoming human trials are seen as a critical 'monumental breakthrough' that would de-risk the entire age-reversal sector and attract a flood of new investment.